Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-10-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-0420PMID 26519060PMCID PMC4681601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

  2015cited by this paper
• Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

  2015cited by this paper
• Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy

  2015cited by this paper
• Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• [Prognostic significance of tryptophan catabolism in adult T-cell leukemia/lymphoma].

  2015cited by this paper
• The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.

  2015cited by this paper
• Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

  2014cited by this paper
• Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

  2014cited by this paper
• Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

  2014cited by this paper
• IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

  2014cited by this paper
• Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1

  2014cited by this paper
• MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma

  2014cited by this paper
• Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

  2014cited by this paper
• Effects of Indoleamine 2,3-Dioxygenase Deficiency on High-Fat Diet-Induced Hepatic Inflammation

  2013cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

  2013influential reference
• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

  2013cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013influential reference
• Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas.

  2013cited by this paper
• Differential expression and regulation of Tdo2 during mouse decidualization.

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

  2013cited by this paper
• Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• IDO inhibits a tryptophan sufficiency signal that stimulates mTOR

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

  2012cited by this paper
• Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

  2011cited by this paper
• Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

  2011influential reference
• IDO Induces Expression of a Novel Tryptophan Transporter in Mouse and Human Tumor Cells

  2011cited by this paper
• Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

  2010influential reference
• Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

  2010cited by this paper
• Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

  2010cited by this paper
• Correction: IDO Mediates Tlr9-Driven Protection From Experimental Autoimmune Diabetes

  2010cited by this paper
• IDO Mediates TLR9-Driven Protection from Experimental Autoimmune Diabetes1

  2009cited by this paper
• The aryl hydrocarbon receptor complex and the control of gene expression.

  2008cited by this paper
• Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.

  2008cited by this paper
• Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

  2008cited by this paper
• IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

  2008cited by this paper
• Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

  2007influential reference
• Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

  2007cited by this paper
• Evolution of Vertebrate Indoleamine 2,3-Dioxygenases

  2007cited by this paper
• Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice.

  2007influential reference
• Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis.

  2007cited by this paper
• A high‐affinity, tryptophan‐selective amino acid transport system in human macrophages

  2006cited by this paper
• The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of s

  2006cited by this paper
• Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase.

  2006cited by this paper
• An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

  2006cited by this paper
• Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

  2005cited by this paper
• GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

  2005cited by this paper
• Natural versus adaptive regulatory T cells.

  2005cited by this paper
• Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1

  2005cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells

  2003cited by this paper
• Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

  2003cited by this paper
• Tolerance, DCs and tryptophan: much ado about IDO.

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase

  2002cited by this paper
• T cell apoptosis by tryptophan catabolism

  2002cited by this paper
• Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

  2002cited by this paper
• Phenotype, Localization, and Mechanism of Suppression of CD4+CD25+ Human Thymocytes

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation

  2000cited by this paper
• Identification and Functional Characterization of a Na+-independent Neutral Amino Acid Transporter with Broad Substrate Selectivity*

  1999cited by this paper
• Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism

  1999cited by this paper
• Prevention of allogeneic fetal rejection by tryptophan catabolism.

  1998cited by this paper
• Sequence of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat.

  1995cited by this paper
• Identification of Tryptophan 2,3‐Dioxygenase RNA in Rodent Brain

  1993cited by this paper
• Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism

  1991cited by this paper
• Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha.

  1990cited by this paper
• Indoleamine 2,3-dioxygenase. Purification and some properties.

  1978influential reference
• The hormonal control of tryptophan peroxidase in the rat.

  1955cited by this paper
• The hormonal control of tryptophan peroxidase in the rat.

  1955cited by this paper

• The role of gut microbiota in liver metastasis of small cell lung cancer: mechanisms and therapeutic implications.

  2026cites this paper
• LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

  2026cites this paper
• Natural resources, chemical synthesis, chemo-bio transformations, metabolism, pharmacology, toxicology, and the underlying mechanisms of curdione.

  2026cites this paper
• “Molecular pigeon” network of lncRNA and miRNA: decoding metabolic reprogramming in patients with lung cancer

  2025cites this paper
• Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer

  2025cites this paper
• Addressing Immune Response Dysfunction in an Integrated Approach for Testing and Assessment for Non-Genotoxic Carcinogens in Humans: A Targeted Analysis

  2025cites this paper
• A scientometric analysis of global research on gut microbiota and glioma

  2025cites this paper
• Genetically Predicted 1400 Blood Metabolites in Relation to Risk of Prostate Cancer: A Mendelian Randomization Study

  2025cites this paper
• Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis

  2025cites this paper
• Revisiting tryptophan metabolism in cancer: complexity, context, and spatial heterogeneity.

  2025cites this paper
• Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance

  2025cites this paper
• Polyphenol-based pH-responsive nanoparticles enhance chemo-immunotherapy in pancreatic cancer.

  2025cites this paper
• Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205

  2025cites this paper
• Phototherapy in cancer treatment: strategies and challenges

  2025cites this paper
• Targetable axes of tumor-associated macrophages: An MSF framework for precision immunotherapy.

  2025cites this paper
• Immunomodulatory mechanisms driving tumor escape in Glioblastoma: the central role of IDO and tryptophan metabolism in local and systemic immunotolerance.

  2025cites this paper
• Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC)

  2025cites this paper
• Biomarkers of pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis through single-cell transcriptomics

  2025cites this paper
• Non-coding RNAs in epithelial-mesenchymal transition of renal cell carcinoma (Review)

  2025cites this paper
• Tryptophan metabolite atlas uncovers organ, age, and sex‐specific variations

  2025cites this paper
• Dual roles of amino acid metabolic reprogramming in chronic airway diseases and lung cancer: therapeutic opportunities and challenges

  2025cites this paper
• Gli1 regulates fibro/adipogenic progenitor function through modulation of Ido1 in muscle regeneration

  2025cites this paper
• Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)

  2025cites this paper
• Strategies to enhance the effects of nanotechnology-mediated photodynamic therapy.

  2025cites this paper
• IDO1-mediated AhR activation up-regulates pentose phosphate pathway via NRF2 to inhibit ferroptosis in lung cancer.

  2025cites this paper
• Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy

  2025cites this paper
• Metabolic disorder of nutrients—an emerging field in the pathogenesis of preeclampsia

  2025cites this paper
• Endoplasmic reticulum stress orchestrates tumor metabolism and immunity: new insights into immunometabolic therapeutics

  2025cites this paper
• Immunohistochemical Profiling of IDO1 and IL4I1 in Head and Neck Squamous Cell Carcinoma: Interplay for Metabolic Reprogramming?

  2025cites this paper
• Recent advances in targeting protein degradation for tumor immunotherapy

  2025cites this paper
• Immunomodulatory behavior of CircRNAs in tumor microenvironment

  2025cites this paper
• Integrated analysis of bulk and single-cell RNA sequencing reveals the impact of nicotinamide and tryptophan metabolism on glioma prognosis and immunotherapy sensitivity

  2024cites this paper
• Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer

  2024cites this paper
• Indoleamine 2,3-dioxygenase-1 involves in CD8+T cell exhaustion in glioblastoma via regulating tryptophan levels.

  2024cites this paper
• DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment

  2024cites this paper
• The central role of transfer RNAs in mistranslation

  2024cites this paper
• Coprococcus eutactus screened from healthy adolescent attenuates chronic restraint stress-induced depression-like changes in adolescent mice: Potential roles in the microbiome and neurotransmitter modulation.

  2024cites this paper
• Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis

  2024cites this paper
• AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma

  2024cites this paper
• Mathematical Modeling of Genistein's Inhibitory Effects on the Tryptophan Pathway: Enzyme Blockage and NAD Dynamics

  2024cites this paper
• Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options.

  2024cites this paper
• Ultrabright and ultrafast afterglow imaging in vivo via nanoparticles made of trianthracene derivatives

  2024cites this paper
• Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer

  2024cites this paper
• Tryptophan metabolite atlas uncovers organ, age, and sex-specific variations

  2024cites this paper
• Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation.

  2024cites this paper
• CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors.

  2024cites this paper
• Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases

  2024cites this paper
• Tryptophan Metabolism and Gut Microbiota: A Novel Regulatory Axis Integrating the Microbiome, Immunity, and Cancer

  2023cites this paper
• Discovery of the sEH Inhibitor Epoxykynin as a Potent Kynurenine Pathway Modulator

  2023cites this paper
• Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy

  2023cites this paper
• Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.

  2023cites this paper
• The role of amino acid metabolism alterations in pancreatic cancer: From mechanism to application.

  2023cites this paper
• KYNU-related transcriptome profile and clinical outcome from 2994 breast tumors

  2023cites this paper
• Leishmania major centrin knock-out parasites reprogram tryptophan metabolism to induce a pro-inflammatory response

  2023cites this paper
• Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug

  2023cites this paper
• Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study

  2023cites this paper
• Simultaneous assaying of NLG919, tryptophan and kynurenine by ultrahigh performance LC-MS in pharmacokinetics and biodistribution studies.

  2023cites this paper
• Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer

  2023cites this paper
• Recent Developments in Nanoparticle‐Based Photo‐Immunotherapy for Cancer Treatment

  2023cites this paper
• Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma

  2023cites this paper
• IDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growth.

  2023cites this paper
• Optimizing CAR-T Therapy for Glioblastoma

  2023cites this paper
• Kynureninase Promotes Immunosuppression and Predicts Survival in Glioma Patients: In Silico Data Analyses of the Chinese Glioma Genome Atlas (CGGA) and of the Cancer Genome Atlas (TCGA)

  2023cites this paper
• Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications

  2023cites this paper
• Pretreated Mesenchymal Stem Cells and Their Secretome: Enhanced Immunotherapeutic Strategies

  2023cites this paper
• Application of Cyclodextrin for Cancer Immunotherapy

  2023cites this paper
• Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects

  2023cites this paper
• Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy

  2023cites this paper
• Exosome from IFN-γ-Primed Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Improved Skin Inflammation and Barrier Function

  2023cites this paper
• Cancer Metabolism under Limiting Oxygen Conditions.

  2023cites this paper
• Metabolic dialogs between B cells and the tumor microenvironment: Implications for anticancer immunity.

  2023cites this paper
• The Potential Strategies for Overcoming Multidrug Resistance and Reducing Side Effects of Monomer Tubulin Inhibitors for Cancer Therapy.

  2023cites this paper
• Immunological Landscape of HER-2 Positive Breast Cancer

  2022cites this paper
• The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies

  2022cites this paper
• Correlation Between Immune-Related Genes and Tumor-Infiltrating Immune Cells With the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

  2022cites this paper
• Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy.

  2022cites this paper
• Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia

  2022cites this paper
• Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

  2022cites this paper
• Potential Pro-Tumorigenic Effect of Bisphenol A in Breast Cancer via Altering the Tumor Microenvironment

  2022cites this paper
• Tryptophan depletion results in tryptophan-to-phenylalanine substitutants

  2022cites this paper
• Specialized interferon action in COVID-19

  2022cites this paper
• L-kynurenine as a prognostic marker for early mortality in patients with acute myeloid leukemia

  2022cites this paper
• Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

  2022cites this paper
• The Role of NcRNAs to Regulate Immune Checkpoints in Cancer

  2022cites this paper
• Gamma delta (γδ) T cells in cancer immunotherapy; where it comes from, where it will go?

  2022cites this paper
• Nanoparticle‐Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy

  2022cites this paper
• Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

  2022cites this paper
• Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma

  2022cites this paper
• Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy

  2022cites this paper
• Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients

  2022cites this paper
• Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells

  2022cites this paper
• T Lymphocyte Infiltration in Association with IDO1 Expression in Resected Lung Adenocarcinoma and Normal Adjacent Lung Tissues

  2022cites this paper
• Tyk2 is a tumor suppressor in colorectal cancer

  2022cites this paper
• Integrative analysis of metabolome and gut microbiota in Patients with pancreatic ductal adenocarcinoma

  2022cites this paper
• USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer

  2022cites this paper
• Identification of a Novel Pseudo‐Natural Product Type IV IDO1 Inhibitor Chemotype

  2022cites this paper
• Kynurenines in polycystic kidney disease

  2022cites this paper
• Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

  2022cites this paper
• Leishmania major centrin knock-out parasites alter the kynurenine- aryl hydrocarbon receptor signaling to produce a pro-inflammatory response

  2022cites this paper
• The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression

  2022cites this paper